FTSE MIB
34.588,53 +128,01 (+0,37%) Dow Jones
39.671,04 -201,95 (-0,51%) Nasdaq
16.801,54 -31,08 (-0,18%) Nikkei 225
39.103,22 +486,12 (+1,26%) Petrolio
77,85 +0,28 (+0,36%) Bitcoin EUR
64.261,96 -281,86 (-0,44%)
Prime Medicine, Inc. (PRME)
Dopo ore:
| Chiusura precedente | 8,03 |
| Aperto | 8,08 |
| Denaro | 7,41 x 300 |
| Domanda | 7,46 x 400 |
| Min-Max giorno | 7,42 - 8,12 |
| Intervallo di 52 settimane | 4,11 - 17,20 |
| Volume | |
| Media Volume | 745.324 |
| Capitalizzazione | 894,231M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,18 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 14,10 |
GlobeNewswirePrime Medicine to Present at Upcoming Investor Conferences
Cambridge, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present at three upcoming investor conferences: BMO Biopharma Virtual Spotlight Series: Latest Advances in Genome / Epigenome Editing: Fireside chat on Tuesday, September 26, 2023, at 10
- GlobeNewswire
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio’s shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBR
- GlobeNewswire
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs™ for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome
-- Collaboration combines Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy Pairs™ (SCIP™) platform -- -- Aim to reduce toxicity of conditioning regimens and introduce new therapeutic options that can expand the utility of hematopoietic stem cell (HSC) transplant and in vivo genetic therapies -- CAMBRIDGE, Mass. and BASEL, Switzerland, June 22, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delive
